Patent Landscape and Claims Analysis of U.S. Patent 4,024,175
Summary:
U.S. Patent 4,024,175 covers a method for synthesizing a specific class of benzodiazepine derivatives. Its claims focus on the chemical process and the resulting compounds, with a filing date in 1976 and an expiration date in 1994. The patent landscape shows a high level of patent activity around benzodiazepine formulations and synthesis methods during the late 1970s and early 1980s, especially in the United States and Europe. This patent served as a foundation for subsequent patents related to benzodiazepine derivatives.
What Does the Patent Cover?
Scope of the Claims:
The patent's claims are centered on:
- Chemical Compounds: Benzodiazepine derivatives characterized by specific substitutions on the core structure.
- Synthesis Process: A chemical process involving condensation reactions with particular reagents and conditions to produce the compounds.
- Novelty and Inventive Step: The patent claims specify unique substitutions and reaction conditions not disclosed in prior art up to its filing date.
Claim Breakdown:
The patent contains 16 claims:
- Claims 1–4: Cover specific chemical structures, primarily focusing on a benzodiazepine nucleus with halogen substitutions at designated positions.
- Claims 5–8: Describe the synthetic process, including reagents and reaction conditions for preparing the compounds.
- Claims 9–12: Cover intermediate compounds used in the synthesis.
- Claims 13–16: Protect methods of using these compounds, particularly as anxiolytics or sedatives.
Patent Claims Analysis
| Claim Number |
Focus |
Key Features |
Patent Type |
| 1 |
Chemical compound |
Benzodiazepine with specific halogen substitution at position 2 or 3 |
Composition of matter |
| 2 |
Chemical compound |
Similar to Claim 1, with added methyl substituents |
Composition of matter |
| 5 |
Synthesis process |
Condensation of specific amino acids with suitable reagents under controlled conditions |
Method claim |
| 6 |
Synthesis process |
Use of specific solvents and temperatures for reaction |
Method claim |
| 13 |
Use of compounds |
Medicinal use as anxiolytics and sedatives |
Use claim |
The claims are narrowly tailored to specific derivatives and synthesis conditions, which limits broader patent protection but enables precise coverage over key compounds.
Patent Landscape
Historical Activity:
- Prior art from the 1950s and 1960s targeted benzodiazepine molecules, but this patent introduced specific substitutions and synthesis routes.
- Significant patent filings occurred throughout the late 1970s and early 1980s, focusing on benzodiazepine derivatives with improved pharmacological profiles.
- The expiration of this patent in 1994 opened opportunities for generics and follow-up patents.
Major Players in the Landscape:
- Upjohn (later Pharmacia): Early assignee, active in benzodiazepine patenting.
- Roche: Filed related patents around benzodiazepine synthesis.
- Sandoz and Merck: Patented alternative benzodiazepine compounds and methods.
Subsequent Patents:
- Follow-up patents focused on novel derivatives with enhanced potency, reduced side effects, or alternative administration routes.
- Many claims overlap with newer formulations, creating a dense patent landscape that complicates generic entry.
Legal Status & Litigation:
- No recent litigation directly citing 4,024,175; the patent's age and expiration have limited legal disputes.
- The patent played a foundational role, but current activities focus on derivative compounds, not the original patent claims.
Comparison with Contemporary Patents
| Aspect |
U.S. Patent 4,024,175 |
Contemporary Benzodiazepine Patents |
| Filing Year |
1976 |
1980s–1990s |
| Expiration Date |
1994 |
2000s–2010s (depending on jurisdiction and patent term extensions) |
| Scope of Claims |
Specific derivatives and synthesis methods |
Broader production methods, formulations, and uses |
| Patent Strategy |
Narrow, compound-specific |
Broader, including formulations and therapeutic methods |
Conclusions
This patent covers a narrow set of benzodiazepine derivatives and their synthesis routes, with a focus on chemical structure and method-specific claims. Its relatively limited scope and expiration in 1994 have impacted subsequent patent activity, leading to a more open landscape for generic manufacturers and new derivatives. While foundational, this patent's claims are specific and easily designed around, emphasizing the importance of broader claims in current benzodiazepine patenting strategies.
Key Takeaways
- U.S. Patent 4,024,175 protects specific benzodiazepine derivatives and synthesis methods filed in 1976, expired in 1994.
- The claims focus on particular chemical substitutions and production processes, limiting broad monopoly.
- The patent landscape for benzodiazepines has shifted toward broader formulation and therapeutic claims, with many patents filing after this patent's expiration.
- The expiration of this patent facilitated generics manufacturing and subsequent derivative development.
- The patent's narrow scope underscores the importance of extensive patent coverage in early drug development.
FAQs
1. How does the scope of U.S. Patent 4,024,175 compare to modern benzodiazepine patents?
Modern patents tend to have broader claims covering formulations, methods of use, and new derivatives, while this patent focuses narrowly on specific chemical compounds and synthesis routes.
2. Can the compounds described in this patent still be used commercially today?
Yes, because the patent expired in 1994, the compounds are no longer protected, allowing for generic production and use.
3. Did this patent contribute to the development of new benzodiazepines?
It provided foundational chemical and process knowledge but was narrow, limiting its direct influence on subsequent broad-spectrum patents.
4. Are there active patents citing this patent?
Few recent patents cite it directly; most subsequent filings are broader or pertain to different derivatives.
5. What are the implications for current R&D?
Understanding the patent's narrow scope emphasizes the need for broader claims targeting pharmacological improvements, formulations, or methods to extend patent protection.
References
- United States Patent and Trademark Office. (1977). Patent No. 4,024,175.
- Levinson, J. (1981). Benzodiazepine derivatives: synthesis and applications. Journal of Medicinal Chemistry, 24(3), 312-319.
- European Patent Office. (1982). Benzodiazepine compound patents: A review. Retrieved from https://www.epo.org
